AR061107A1 - Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida - Google Patents

Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida

Info

Publication number
AR061107A1
AR061107A1 ARP070102226A ARP070102226A AR061107A1 AR 061107 A1 AR061107 A1 AR 061107A1 AR P070102226 A ARP070102226 A AR P070102226A AR P070102226 A ARP070102226 A AR P070102226A AR 061107 A1 AR061107 A1 AR 061107A1
Authority
AR
Argentina
Prior art keywords
humanized
integrin
human
antibody
function
Prior art date
Application number
ARP070102226A
Other languages
English (en)
Inventor
Andreas Menrad
Dieter Zopf
Joerg Willuda
Klaus Bosslet
Heike Petrul
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of AR061107A1 publication Critical patent/AR061107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Polipéptidos recombinantes humanos o humanizados que se unen a la integrina alfa5beta1 con gran afinidad y bloquean su funcion. Además, se describen aplicaciones de diagnostico y farmacéutico de los polipéptidos Reivindicacion 1: Un anticuerpo humano o humanizado, o un fragmento de union al antígeno del mismo, que se une a la integrina alfa5beta1 con una afinidad <=100 nM y que inhibe la adhesion de las células que expresan integrina alfa5beta1 a su receptor in vitro e in vivo. Reivindicacion 21: El anticuerpo, o fragmento de anticuerpo, de cualquiera de las reivindicaciones 1-17 en la forma de un polipéptido de fusion. Reivindicacion 24: El anticuerpo, o fragmento de anticuerpo, de la reivindicacion 23, en donde el grupo de marcacion detectable se selecciona entre grupos de marcacion radioactivos, NMR, colorantes, enzimas y fluorescentes.
ARP070102226A 2006-05-24 2007-05-23 Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida AR061107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
AR061107A1 true AR061107A1 (es) 2008-08-06

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102226A AR061107A1 (es) 2006-05-24 2007-05-23 Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP2007000101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628116A1 (en) 2005-10-31 2007-12-13 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
EP2641612A1 (en) * 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2742861A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
US8124740B2 (en) * 2009-03-25 2012-02-28 Genentech, Inc. Anti- α5 β1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9211344B2 (en) * 2010-07-09 2015-12-15 Affibody Ab Polypeptides
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN104994874B (zh) * 2012-12-26 2017-04-12 安科协同公司 抗整联蛋白β1抗体组合物及其使用方法
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
EP3916014A4 (en) * 2019-07-24 2022-10-26 Korea Basic Science Institute SINGLE DOMAIN ANTIBODIES TARGETED AGAINST AVSS3 INTEGRIN
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
DK1755659T3 (da) * 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
CA2646611A1 (en) * 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy

Also Published As

Publication number Publication date
EP2032605A2 (en) 2009-03-11
CA2652886A1 (en) 2007-11-29
CR10456A (es) 2009-02-26
WO2007134876A3 (en) 2008-03-27
ZA200810850B (en) 2010-05-26
MX2008014910A (es) 2009-01-23
DOP20070101A (es) 2007-12-30
ECSP088909A (es) 2008-12-30
TNSN08469A1 (en) 2010-04-14
DOP2007000101A (es) 2007-12-31
BRPI0711796A2 (pt) 2011-12-06
CN101495515A (zh) 2009-07-29
AU2007253586A1 (en) 2007-11-29
KR20090027218A (ko) 2009-03-16
WO2007134876A2 (en) 2007-11-29
UY30362A1 (es) 2008-01-02
TW200817433A (en) 2008-04-16
CL2007001488A1 (es) 2008-01-04
NO20085362L (no) 2009-02-23
MA30425B1 (fr) 2009-05-04
PE20080100A1 (es) 2008-04-18
JP2009537158A (ja) 2009-10-29
US20090081207A1 (en) 2009-03-26
WO2007134876A8 (en) 2009-07-02
EA200802348A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
AR061107A1 (es) Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida
Bazan et al. Phage display—A powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications
AR076797A1 (es) Anticuerpos triespecificos o tetraespecificos
PE20140218A1 (es) Composicion farmaceutica
UY29770A1 (es) Polipéptidos y anticuerpos
CL2021001986A1 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1).
RS53752B1 (en) ANTITELO PROTIV ILT7
CL2016002624A1 (es) Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011)
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AR077088A1 (es) Proteinas biespecificas de union a antigeno
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
RS54424B1 (en) HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES
ATE178097T1 (de) Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen
AR073538A1 (es) Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
NI201100064A (es) Anticuerpos humanos de la alta afinidad para el receptor il-4 humano fundamento.
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
AR078751A1 (es) Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
UY31433A1 (es) Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas
PE20090368A1 (es) Anticuerpos anti-igf
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
AR029642A1 (es) Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos

Legal Events

Date Code Title Description
FB Suspension of granting procedure